Holen Sie sich die Stockscreener-App
985.08
0.80%
7.83
Handel nachbörslich:
985.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$977.25
Offen:
$980.13
24-Stunden-Volumen:
1.98M
Relative Volume:
0.64
Marktkapitalisierung:
$879.67B
Einnahmen:
$65.18B
Nettoeinkommen (Verlust:
$20.64B
KGV:
43.61
EPS:
22.5894
Netto-Cashflow:
$5.96B
1W Leistung:
-0.53%
1M Leistung:
-5.28%
6M Leistung:
+30.41%
1J Leistung:
+22.88%
1-Tages-Spanne:
$978.00
$1,003.22
1-Wochen-Bereich:
$973.16
$1,012.00
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
985.08 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit” - Insider Monkey
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPenKroger (NYSE:KR), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Boosts Chinese Manufacturing Investments - Advanced Manufacturing
Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program - 富途牛牛
Form Health Joins the Lilly Employer Connect Platform - Yahoo Finance Singapore
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm - The Globe and Mail
Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative - simplywall.st
Eli Lilly tops growth factor grades among S&P healthcare holdings (LLY:NYSE) - Seeking Alpha
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs? - sharewise.com
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - Benzinga
Lilly Flags Safety Risk In Compounded GLP 1 - GuruFocus
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives - GuruFocus
Jim Cramer Answered Questions About 13 Stocks: Eli Lilly, Meta, and More - Insider Monkey
Eli Lilly finds impurity in compounded tirzepatide - Pharmaceutical Technology
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 - Insurance Journal
Health risk alert as weight-loss jab manufacturer issues warning - The Independent
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma
Eli Lilly to invest $125m in Japan plant to boost supply of new drugs - Nikkei Asia
Eli Lilly (LLY) Warns Against Compounded Tirzepatide Products - GuruFocus
KLCM Advisors Inc. Sells 5,592 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Issues Warning on Safety Concerns of Compounded Tirzep - GuruFocus
Roberts Capital Advisors LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
ProQR Announces Year End 2025 Operating and Financial Results - GlobeNewswire Inc.
Health: Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Gulf Daily News
Eli Lilly Expands China Production for Weight Management Drugs | 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Eli Lilly and Company finds impurity in compounded diabetes and obesity drug knockoffs - Traders Union
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Reuters
Eli Lilly to invest USD 3bn in China - medwatch.com
PHARMARON Surges 12%+ After Reaching Production Co-op Agreement with Eli Lilly for Orforglipron - AASTOCKS.com
Pharmaron opens higher after reaching a production cooperation agreement for Orforglipron with Eli Lilly and Co. - 富途牛牛
Lilly to Invest $3 Billion in China to Boost Obesity Pill - Bloomberg.com
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia - The Manila Times
Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud - Law360
Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro - Insider Monkey
Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 - GuruFocus
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 - Fierce Pharma
Lilly introduces direct-to-employer program for weight-loss drug - Indianapolis Business Journal
Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval - Pharmaceutical Technology
Eli Lilly (LLY) to Invest $3B in China for Weight Loss Drug Expa - GuruFocus
Eli Lilly's $3B China Investment for GLP-1 Drug Production | 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there - Endpoints News
Eli Lilly (LLY) Submits Weight Loss Drug Application in China - GuruFocus
Wolfe bumps Eli Lilly target on oral obesity drug, cardiometabolic portfolio - Investing.com Nigeria
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound - Benzinga
Hims & Hers taps ex-Eli Lilly PR chief to lead communications - medwatch.com
Kepler Cheuvreux Suisse SA Invests $3.10 Million in Eli Lilly and Company $LLY - MarketBeat
Bernstein Maintains Outperform on Eli Lilly (LLY) March 2026 - Meyka
Eli Lilly and Company $LLY Shares Sold by First Trust Advisors LP - MarketBeat
Financial Life Planners Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):